The present results, by providing a mechanistic rationale for the combination, indicate that the combination of the inhibitors of MDM4 expression with those targeting the p53–MDM2 interaction is a rational strategy to efficiently reactivate the p53 pathway in wild-type p53 cancer cells. This evidence concerns the gene TP53 and cancer.